Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of March 2026, specifically reporting transaction notifications for Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs). The filing was signed on March 23, 2026.
Key Financial Metrics
This filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details insider trading activity.
| Instrument | Exchange | Transaction Date | Price | Volume |
|---|---|---|---|---|
| Ordinary Shares (GBP) | London Stock Exchange | 2026-03-20 | £19.5085 - £19.5136 | 5,000 |
| Ordinary Shares (GBP) | London Stock Exchange | 2026-03-20 | £19.6250 | 411 |
| Ordinary Shares (GBP) | London Stock Exchange | 2026-03-18 | £19.6294 | 6,335 |
| American Depositary Shares (USD) | New York Stock Exchange | 2026-03-20 | $51.7939 | 2,920 (Aggregated) |
Material Changes
The filing reports multiple purchases of GSK securities by Non-Executive Directors on March 18 and March 20, 2026. There are no material changes to the company's financial position or operations disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider transactions.
Key Facts for Investor Verification
- Insider Sentiment: Multiple Non-Executive Directors (including Sir Jonathan Symonds, Wendy Becker, and Dr. Gavin Screaton) purchased shares on March 18 and 20, 2026.
- Share Price: Ordinary shares traded between approximately £19.51 and £19.63 on the London Stock Exchange during the reporting period.
- ADS Price: American Depositary Shares traded at $51.7939 on the New York Stock Exchange on March 20, 2026.
- Transaction Type: All reported transactions were purchases; no sales were disclosed in this filing.